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Abstract
Genome-wide association studies have identified a genetic variant at 3p14.3 (SNP
rs1354034) that strongly associates with platelet number and mean platelet volume in
humans. While originally proposed to be intronic, analysis of mRNA expression in primary
human hematopoietic subpopulations reveals that this SNP is located directly upstream of
the predominantly expressed ARHGEF3 isoform in megakaryocytes (MK). We found that
ARHGEF3, which encodes a Rho guanine exchange factor, is dramatically upregulated dur-
ing both human and murine MK maturation. We show that the SNP (rs1354034) is located
in a DNase I hypersensitive region in human MKs and is an expression quantitative locus
(eQTL) associated with ARHGEF3 expression level in human platelets, suggesting that it
may be the causal SNP that accounts for the variations observed in human platelet traits and
ARHGEF3 expression. In vitro human platelet activation assays revealed that rs1354034 is
highly correlated with human platelet activation by ADP. In order to test whether ARHGEF3
plays a role in MK development and/or platelet function, we developed an Arhgef3 KO/LacZ
reporter mouse model. Reflecting changes in gene expression, LacZ expression increases
during MK maturation in these mice. Although Arhgef3 KO mice have significantly larger
platelets, loss of Arhgef3 does not affect baseline MK or platelets nor does it affect platelet
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function or platelet recovery in response to antibody-mediated platelet depletion compared to
littermate controls. In summary, our data suggest that modulation of ARHGEF3 gene expres-
sion in humans with a promoter-localized SNP plays a role in human MKs and human platelet
function—a finding resulting from the biological follow-up of human genetic studies. Arhgef3
KO mice partially recapitulate the human phenotype.
Introduction
Genome-wide association studies (GWAS) identify genomic polymorphisms associated with
specific phenotypes and diseases in humans.[1–3] The description of these loci holds promise
for the identification of important biological pathways and disease mechanisms. GWAS stud-
ies in humans have identified hundreds of single nucleotide polymorphisms (SNPs) associated
with the number of platelets per unit blood volume (platelet count, PLT) and platelet size
(mean platelet volume, MPV), which show natural variation in humans and are heritable traits.
[4–8] One of the SNPs showing the strongest association with PLT and MPV in humans
resides in the in the locus for the guanidine exchange factor ARHGEF3. The GWAS associa-
tion signal indicated a potential functional role of this GEF protein in megakaryopoiesis and
the formation and function of platelets. To assess for a functional role of ARHGEF3, we gener-
ated Arhgef3 knock-out mice. In order to further examine the potential functional outcome in
human platelets, we analyzed the experimental results from the BLUEPRINT epigenome study
and from the Cambridge Platelet Function cohort and the PRAX1 expression QTL study.
ARHGEF3 encodes for the Rho Guanine Nucleotide Exchange Factor 3, also known as the
Exchange Factor Found in Platelets, Leukemic, and Neuronal tissues (XPLN).[9] It regulates
the switch of Rho GTPase from the inactive GDP-bound state to the active GTP-bound state,
and is one of the most abundant GEFs found in human MK lineage [7, 8] and platelets.[9] It
has also been implicated as playing a role in myeloid differentiation.[10] Published microarray
data and western blot analyses confirm that ARHGEF3 is highly expressed in platelets.[9, 11]
However, whether ARHGEF3 plays a role in megakaryocyte development, platelet formation
and/or platelet function in mammals has not been reported.
Here, we used insights from human genetics to study the function of ARHGEF3 in primary
murine and human megakaryocytes and platelets. We created an Arhgef3 knockout (KO)
mouse model with interruption of the endogenous gene by insertion of LacZ reporter cDNA.
We found that Arhgef3 KO mice have normal MK maturation and platelet function. However,
KO mice have enlarged platelets and a mild delay in platelet recovery in response to thrombo-
cytopenia. In the human system, we found that the rs1354034 SNP of ARHGEF3 is an expres-
sion quantitative trait locus (eQTL) that strongly correlates with ADP induced fibrinogen
binding of platelets in vitro. In addition, we show that rs1354034 may perturb function by dis-
rupting protein binding to DNA in human MKs. Here we present evidence suggesting that
ARHGEF3 plays an important role in human megakaryocytes and platelets. However, ARH-
GEF3 is less critical in murine megakaryocytes and platelets.
Results
ARHGEF3 is upregulated during MK differentiation
To study the function of ARHGEF3 in mammalian megakaryocytes and platelets, we first
determined the expression level of ARHGEF3 during megakaryocyte development. By
ARHGEF3 in megakaryocytes and platelets
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Quantitative-RT-PCR (qRT-PCR) and western blot analysis, both ARHGEF3 RNA and pro-
tein were highly enriched in the pellet fraction (most highly enriched for mature MKs as
shown by the CD41 level) compared to the 3% fraction of the differentiated fetal liver cells
(p<0.005), suggesting that mature megakaryocytes express high ARHGEF3 (Fig 1A and 1B).
We further studied human cells, where published microarray data on CD34-derived cells that
had been differentiated in vitro down the MK lineage showed that ARHGEF3 mRNA levels
increased during MK maturation (Fig 1C).[12] RNA sequencing on eight human hematopoi-
etic progenitor populations, performed by the BLUEPRINT consortium, revealed the highest
levels of ARHGEF3 expression in MK. The predominant isoform in MK (light blue, ENST
00000296315, Fig 1D) is the second longest annotated transcript with a transcription start site
in exon 5 of the longest transcript.[13] ARHGEF3 transcript 001 (ENST00000296315) has a
posterior probability of being MK-specific of 0.996470891 with an estimated log fold change
(relative all other cell types) of 2.66. [13]
Fig 1. ARHGEF3 expression in primary murine and human cells. (A-B) ARHGEF3 mRNA and protein levels were assessed in
megakaryocytes derived in vitro from WT E13.5 fetal liver cells. A 3% BSA gradient was used to separate megakaryocytes (MKs). Both
CD41 (positive control) and ARHGEF3 expression are increased in the pellet fractions compared to the 3% BSA fraction (p < 0.005). (C)
RNA sequencing data from public a database [12] shows ARHGEF3 upregulation during human CD34+ differentiation down the MK
lineage. (D) Barplots representing transcript isoform expression levels across eight human hematopoietic cell types.[13] ARHGEF3
expression (represented by the total height of the barplots) increases during megakaryocytic lineage differentiation and the most
abundant transcript isoform in megakaryocytes is ENST00000296315. The figure includes Ensembl v70 annotated transcripts and those
annotated as non-protein coding or nonsense mediated decay have been grouped together. [HSC: hematopoietic stem cell, MPP:
multipotent progenitor, CLP: common lymphoid progenitor, CMP: common myeloid progenitor, GMP: granulocyte monocyte progenitor,
MEP: megakaryocyte erythrocyte progenitor, EB: erythroblasts and MK: megakaryocytes.]
https://doi.org/10.1371/journal.pone.0178095.g001
ARHGEF3 in megakaryocytes and platelets
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SNP rs1354034 is a leading SNP associated with ARHGEF3 expression
level
To further address whether ARHGEF3 plays a role in human MK and platelets, we confirmed
the association between platelet count and genetic variation at the SNP (rs1354034) upstream
of the ARHGEF3 gene. A 400kb region containing ARHGEF3 gene was resequenced in 500
people with sex-adjusted low platelet counts and 500 people with sex-adjusted high platelet
counts. These healthy subjects represent the 5% tails of the age adjusted platelet distribution in
the Dutch LifeLines Cohort Study [14] (for which platelet count had been measured in 94,753
study subjects). The SNP rs1354034 had the lowest p-value (p = 7.10×10−6) in a one variant at a
time analysis testing for association between platelet distribution tail status (high/low) and
genotype using Fisher’s exact test (Fig 2A), with 56%, 52% and 32% of CC, CT and TT geno-
types respectively corresponding to study subjects in the upper 5% tail of platelet count (data
not shown), thus the C-allele is associated with higher platelet counts. The association between
Fig 2. rs1354034 is the leading SNP and an eQTL for ARHGEF3 expression. (A) Visual summary of the statistical evidence for variant-
phenotype association at the locus of rs1354034 from data generated by the TEMPLE targeted sequencing study. It shows the variant specific
P-values from Fisher’s exact tests against null hypotheses that genotype frequencies are the same in the high and low platelet count samples.
The color of each point represents the r2 between the corresponding variant and rs1354034, estimated from the TEMPLE genotypes. The
continuous line indicates the local recombination rate estimated from HapMap data. (The tool used to generate the plot is available at
doi:10.1093/bioinformatics/btq41.) (B) Shown is rs 1354034 (blue X) and its LD structure in +/- 250 kb window. There is no SNP in linkage
disequilibrium (threshold r2 >0.8) found 250k bp up- or downstream of the rs1354034 locus (data from 1000 Genome Project), suggesting
rs1354034 is the leading SNP of ARHGEF3. (C) A strong association of the rs1354034 genotype with ARHGEF3 mRNA levels (p = 1.37x10-15,
ordinary linear regression). This association stayed significant even after accounting for subject age, gender and race (p = 2.39 x 10−11,
multiple linear regression). Primary data for 5C in online S1 Table.
https://doi.org/10.1371/journal.pone.0178095.g002
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the common SNP rs1354034 and the traits of mean volume and platelet count (PLT) has been
replicated in two further GWAS. [7, 8] The results of these four independent studies render a
false-positive association unlikely. Moreover, a closer examination of the nearby genomic
region of the target SNP rs1354034 revealed that no other SNPs within 250k bp up/down-
stream of the rs1354034 locus in high linkage disequilibrium (threshold r2 = 0.8, Fig 2B)
suggesting that rs1354034 is the leading SNP responsible for the human platelet variations
observed.
Epigenetic analysis of the chromosome landscape of primary human MKs derived from
CD34+ cord blood further revealed that rs1354034 resides about 15k bp upstream of the active
promoter (at a H3K27 acetylation peak) of the predominant isoform of ARHGEF3 identified
by RNA-seq. This further corroborated that ARHGEF3 transcript ENST00000296315 is ex-
pressed in MKs, and suggested that the SNP may perturb regulation of the expression of the
ARHGEF3 gene. We therefore assessed the association between ARHGEF3 haplotype and
mRNA levels by comparing the transcriptomes of platelets from individuals of different geno-
types. Data from the PRAX1 study on 154 healthy human subjects [11] showed that rs1354034
is strongly associated (p<0.001) with ARHGEF3 expression in platelets (Fig 2C). Further anal-
ysis within the population showed that the allele frequencies of SNP rs1354034 are differen-
tially distributed across different ethnicities in the human population (S1 Fig). The fact that
the same haplotype associates with hematological platelet parameters and ARHGEF3 expres-
sion provides strong evidence that the differences in platelet count and volume observed
between genotype groups are mechanistically related to differences in ARHGEF3 levels.
SNP rs1354034 is associated with human platelet function
The positive correlation between platelet volume and functional activity has been hypothesized
and explored in platelet biology.[15] We further performed association studies on the platelet
count and volume loci identified in the GWA studies with the human platelet functional
response to ADP and collagen. Specifically, we tested in the Cambridge platelet function
cohort of just more than 1,200 genome-wide typed individuals, the association between allelic
variants and two functional read-outs by flow cytometry: 1) fibrinogen binding and 2) P selec-
tin expression levels. Platelets were activated with either the collagen mimetic CRP-XL or
ADP. A total of 39,331,925 variants obtained after imputation of the genotypes using the
results of the 1000 Genomes project for reference were tested for association with the four
traits. Four genetically independent variants were identified as being associated with at least
one of the four platelet function traits at P< 5x10-7, with rs1354034 in ARHGEF3 being one of
the four (P values: 6.9 x 10−8 and 5.5 x 10−8 for fibrinogen and P-selectin, respectively). The
levels of functional response are lower in subjects carrying the minor (C) allele of rs1354034. It
is interesting to note that no association signal was observed for these two markers after activa-
tion of platelets by collagen (Fig 3), indicating a highly specific action of ARHGEF3 on signal-
ing events downstream of the G-protein coupled ADP receptors P2RY1 and P2RY12. Thus,
rs1354034 is uniquely associated with fibrinogen binding in response to ADP stimulation.
SNP rs1354034 resides in an open chromatin region and may affect
binding of chromatin-associated proteins in MKs
Because platelets do not have a nucleus, the finding that the genomic locus rs1354034 strongly
associates with human platelet traits (volume, count and function) prompted us to study the
locus in MK from a genomic and epigenetic perspective, using human MK derived in vitro
from CD34+ cord blood. We found that the SNP rs1354034 is located in a DNase I hypersensi-
tive site (Fig 4, green) that is also marked for H3K27ac histone modification (Fig 4, purple),
ARHGEF3 in megakaryocytes and platelets
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suggesting that the SNP lies within a regulatory region and may alter protein binding to this
genomic locus in MK. Examining chromatin immunoprecipitation followed by DNA sequenc-
ing (ChIP-seq) from the ENCODE project (http://genome.ucsc.edu/cgi-bin/hgTrackUi?db=
Fig 3. rs1354034 is associated with human platelet function. (A-C) Association studies on SNPs and
human platelet function. X axis: Genomic position. Y axis: -log10 (P-value from linear additive association).
The three quantitative traits measured by flow cytometry are fibrinogen binding in response to ADP (A) or
Collagen (B) and P-selectin expression in response to Collagen (C). The purple diamond represents the lead
SNP and the colour of the other SNPs is based on the linkage disequilibrium (in terms of r2) with the lead SNP.
https://doi.org/10.1371/journal.pone.0178095.g003
Fig 4. rs1354034 is located in a DNase I hypersensitive region in primary human MKs. Shown is the chromatin locus containing the
ARHGEF3 gene. rs1354034 (orange arrow) is located in an open-chromatin (DNase I peak) non-coding region upstream of the transcription start
site of ENST00000296315 (the most commonly transcribed mRNA in MK, indicated by an asterisk). Green: DNase 1 peaks, Purple: H3K27Ac ChIP
peaks, Blue: intron/exon boundaries, Bottom: major ENST’s identified for ARHGEF3.
https://doi.org/10.1371/journal.pone.0178095.g004
ARHGEF3 in megakaryocytes and platelets
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hg19&g=wgEncodeRegTfbsClusteredV3) for transcription factors for MK maturation (SCL,
RUNX1, MEIS1, GATA2, GATA1, and FLI1 [13, 16]), none of these factors was found to bind
specifically at the SNP site.
Production and validation of Arhgef3 knockout (KO) mice
We produced a global Arhgef3 knockout (KO) mouse model with Arhgef3 KO embryonic stem
(ES) cells purchased from the Knockout Mouse Project Repository (KOMP) (Fig 5A). In these
cells and the mice derived therefrom, the Arhgef3 genomic locus is deleted from exon 5–7 and
is replaced with a splice acceptor (En2SA) followed by an Internal Ribosome Entry Site (IRES),
LacZ cDNA and a poly-adenine sequence (PA). This allows LacZ to serve as a reporter for
expression of the endogenous Arhgef3 gene.
The Arhgef3 global KO mice obtained are fertile and viable, with no obvious developmental
defects. qRT-PCR on freshly isolated bone marrow cells from WT, Arhgef3 heterozygotes
(HET) and homozygotes knockout (KO) mice confirmed that there is a complete loss of Arh-
gef3 mRNA in the KO and a 50% decrease of mRNA level in the heterozygotes (Fig 5B). LacZ
expression in the Arhgef3 KO megakaryocytes (CD41+) was confirmed by immunohistochem-
istry for β-galactosidase and CD41+ (Fig 5C) on day E13.5 mouse embryo liver, consistent
with high ARHGEF3 protein expression in MKs.
Fig 5. ARHGEF3 knockout design and confirmation of Arhgef3 knockout in the megakaryocyte lineage. (A) Arhgef3 KO design from
KOMP: The wild type Arhgef3 gene is disrupted by replacement of exons 5–7 with a gene cassette containing a splice acceptor (En2SA), an
IRES and LacZ cDNA. The neomycin resistance gene has its own beta actin promoter. (B) Arhgef3 KO confirmation: qRT-PCR for Arhgef3
in fresh bone marrow cells from WT, ARHGEF3 heterozygous and homozygous KO mice confirmed the complete loss of ARHGEF3 in the
KO mice. (C) LacZ/β-galactosidase staining on E13 mouse liver from wild type (WT) or Arhgef3 homozygous knockout embryos shows that
Arhgef3 KO MKs are positive for both CD41 (brown) and LacZ/β-galactosidase staining (blue).
https://doi.org/10.1371/journal.pone.0178095.g005
ARHGEF3 in megakaryocytes and platelets
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Arhgef3 KO mice have enlarged platelets, but normal platelet function
We found that there is a small, but statistically significant (p<0.005), increase in mean platelet
volume in KO mice (KO: 5.313 ± 0.03702 fl, n = 31; WT: 4.991 ± 0.1091 fl, n = 11). But, platelet
counts are indistinguishable between WT and KO animals (Fig 6A). We assayed in vitro plate-
let function by flow cytometry with the JONA antibody, which binds specifically to activated
integrin α2bβ3 (inside-out signaling), and anti- P-selectin (CD62), which assesses granule
release, in response to multiple agonists. In the resting state, Arhgef3 KO platelets displayed
higher forward scatter (FSC) than WT (Fig 6B), consistent with the increased platelet volume.
However, there was no significant defect in the Arhgef3 KO versus WT platelet in activation
with any of the agonists tested (Fig 6C). We further tested in vivo platelet function by the tail
bleeding time assay, and no differences were found in the KO compared to WT littermates
(Fig 6D). Taken together, these results indicate that platelet function is normal in the absence
of Arhgef3.
Arhgef3 KO mice have normal MK maturation, but have delayed platelet recovery. We
assessed platelet formation in the absence of ARHGEF3 by monitoring in vivo platelet recovery
following antibody-mediated acute thrombocytopenia. There was no significant effect on time
Fig 6. Arhgef3 KO mice have enlarged platelets, and normal platelet activation. (A) Peripheral blood was taken from 4 week old littermate mice
with the indicated genotypes. Arhgef3 KO mice have significantly larger platelets (MPV) but normal platelet counts. (B) Mean forward side scatter
(FSC) of platelets (gated as CD41/CD61+ from whole blood) confirmed that KO mice have larger platelets. (C) Flow cytometry for Integrin α2bβ3
conformational change (JONA MFI) and P-selectin exposure of platelets from littermate mice in response to ADP, thromboxane (U46), thrombin and
PAR4-AP stimulation. There are no significant differences between WT and Arhgef3 KO platelets with any of the agonists tested. (3 independent
experiments, n = 4/genotype). (D) Tail bleeding times of WT and Arhgef3 KO littermates showed no differences in bleeding time. (WT n = 10, KO
n = 9).
https://doi.org/10.1371/journal.pone.0178095.g006
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to platelet recovery in the KO mice (data not shown). We also assessed bone marrow MK
maturation. Analysis of baseline (unstimulated) bone marrow by flow cytometry revealed no
differences between KO and WT littermates in the percentages of different progenitor popula-
tions, including Lin−Sca+Kit+ stem/progenitor cells, CD41-CD150+CD105- megakaryocyte-
erythroid progenitors (PreMegE) or CD41+Kit+ megakaryocyte progenitors (MKP) (S2A
Fig). To further look into the function of these progenitor cells, we performed analysis for
mature MKs on fresh or in vitro differentiated bone marrow cells from WT and Arhgef3 KO
mice. Again, no differences were found in maturation (co-expression of MK cell surface mark-
ers CD41 and CD42) or DNA ploidy in the bone marrow MK between WT and KO mice (S2B
Fig). Thus, Arhgef3 is not critical for murine MK development.
Discussion
In the present study, we performed follow-up research on one of the top GWA studies hits–
rs1354034 proximal to the gene ARHGEF3, a little known RhoA guanine exchange factor–in
both primary murine and human megakaryocytes and platelets. Although a relevant role of
ARHGEF3 in platelets has been suggested from multiple recent GWA studies in human
cohorts as well as by morpholino knockdown (KD) experiments in the zebrafish [4–6], the
question of whether the manipulation of ARHGEF3 levels alters megakaryocyte or platelet
function in the mouse system has not been assessed, nor is the biological mechanisms of ARH-
GEF3 function in human cells known. Here, we further analyzed the SNP of ARHGEF3 in pri-
mary human megakaryocytes and platelets, and we created a global knockout mouse model of
Arhgef3 in which we analyzed the megakaryocyte and platelet phenotypes.
Several lines of evidence from the literature and our analyses suggest that ARHGEF3 may
play a role in human megakaryocytes and platelets. 1) Our studies show that ARHGEF3 is
upregulated during megakaryocytic differentiation and enriched in mature megakaryocytes in
both mice and humans. 2) The SNP rs1354034 is the leading SNP for the variations of platelet
count and volume. 3) The SNP is an eQTL associated with ARHGEF3 expression level in plate-
lets. 4) The same locus also associates with human platelet function unique to increased fibrin-
ogen binding in response to ADP stimulation. 5) The SNP localizes to a DNase hypersensitive
site in an open chromatin that also localizes H3K27Ac, and thus may regulate ARHGEF3
expression in human megakaryocytes. However, given the “negative” findings of this study, we
cannot yet clarify the mechanism through which genetic variation in ARHGEF3 alters PLT
and MPV in humans. Possiblities include: 1) the SNP affects a unique regulatory network in
human cells that remains to be discovered, 2) ARHGEF3 plays a role in humans that is not
shared in mice, or 3) ARHGEF3 does not effect megakaryocytes or platelets in humans, and
the SNP is affecting something unrelated to the gene in which it is located.
ARHGEF3 deficient mice appear to have normal megakaryocyte development and platelet
function, and restore their platelet counts to baseline similarly to WT mice in response to
acute platelet depletion in vivo. Given that our data demonstrate that the C-allele in rs1354034
is associated with lower ARHGEF3 mRNA expression, higher mean plt count and lower MPV
in humans, we had predicted that Arhgef3 KO would potentially lead to lower platelet counts
and higher MPV in mice. Our findings, however, were that Arhgef3 KO had no effect on
murine platelet counts and a statistically significant increase in the MPV. The mechanisms
underlying this association are not yet clear.
The largely normal megakaryocyte and platelet function of the Arhgef3 KO mice was
surprising, but may be explained by differences in the zebrafish and humans versus mouse
megakaryopoiesis and thrombopoiesis. The same research group that performed Arhgef3 mor-
pholino knockdown (KD) experiment in zebrafish found that in addition to the thrombocyte
ARHGEF3 in megakaryocytes and platelets
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phenotype, Arhgef3 KD also results in abrogation of erythroid maturation.[17] This suggests
that ARHGEF3 may affect early stages of hematopoiesis in the fish. Although humans and
mice are evolutionarily closer, there are of course many differences between the two species
with potentially important biological and translational implications.[18] Thus, a more suitable
model to test the ARHGEF3 SNP might be a transgenic mouse with the same SNP variations
found in humans.
Another possible explanation for the mild phenotype of the Arhgef3 KO is the existence of
compensatory mechanisms related to other guanine exchange factors. The SNP in ARHGEF3
was identified within a healthy cohort, where association of the gene expression level (the SNP
is an eQTL) is identified with variations of platelet traits.[4–6] However, in a mouse system
where the gene is completely knocked out, there may be compensatory mechanisms to prevent
effects due to loss of a critical gene. There are over 80 different GEF proteins expressed in
mammals spatially and temporarily regulating different cellular processes, and all of them tar-
get one of the three main substrate families—Rho, Rac, CDC42.[19] The most highly con-
served GEF to ARHGEF3 is Neuroepithelial Cell Transforming 1 (NET1). When we knocked
down Net1 in Arhgef3 KO murine cells, there was no effect on megakaryocyte maturation sug-
gesting that Net1 does not compensate for Arhgef3 (data not shown).
Also, SNP association studies in different ethnicities reveal that the allele frequencies of
SNP rs1354034 are differentially distributed across different ethnicities in the human popula-
tion (S2 Fig). Previous research has found such ethnic variation in the human population can
be reflected as strain variation in mouse models as well.[20] Hence, the inbred mouse strains
used in research may also influence the observed phenotypes.
In this study, we further examined ARGHEF3 in human cells. We found that the ARHGEF3
SNP strongly associates with ADP-stimulated fibrinogen binding but not collagen-stimulated
fibrinogen binding or P-selectin exposure in human platelets. The two agonists activate two
distinct signaling cascades leading to platelet activation. Collagen activates platelets via GPVI
(GP6) and FcRγ/ITAM (FCER1G) signaling cascade [21, 22] while ADP amplifies the activa-
tion of platelets through its binding to the two G protein–coupled receptors, P2Y12 and P2Y1.
P2Y12, through activating GTP-bound α subunit Gαi, suppresses cAMP formation so that
platelet activation can occur. P2Y1, activates phospholipase C through GTP-bound α subunit
Gαq, which moderates Calcium release.[23] Platelets from mice lacking P2Y1 do not undergo
shape change in response to ADP,[24] suggesting that ADP signaling is involved in platelet
shape change, mechanism of which is unclear. Given that platelet shape change is mediated
through Rho signaling and actin reorganization,[25] it is reasonable to hypothesize that ARH-
GEF3 may be the missing link between ADP signaling through P2Y1 receptor and Rho-medi-
ated shape change in human platelets. Interestingly, in another genome-wide association
study, the same SNP, rs1354034 on chromosome 3, was found to be associated in trans with
expression levels of von Willebrand Factor (vWF), an important blood coagulation gene on
chromosome 12, with a P value of 5.43 × 10−5.[26] This further supports that rs1354034 corre-
lates with human platelet function.
In summary, based on previously published GWA studies and the published morpholino
knockdown experiments in the zebrafish, we tested the function of ARHGEF3 in both murine
and human megakaryocytes and platelets. While there was no phenotype in the mice aside from
an unexpected increase in MPV, our study suggests new hypotheses for further validation and
studies of the molecular mechanism of the SNP locus in human MK development and the role
of ARHGEF3 in human platelet activation, especially testing the hypothesis that ARHGEF3 is
downstream of ADP stimulated P2Y1 and Gαq activation to mediate Rho activity for platelet
shape change. Our study also proposes that transgenic mouse models with the same SNP varia-
tions, when possible, would be better models for mimicking gene variations in humans.
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Materials and methods
Mice
ARHGEF3 knockout ES cells (https://www.komp.org/pdf.php?projectID=39618, derived from
JM8A3.N1 ES cells, strain background: C57BL/6N-Atm1Brd, which is essentially Bl6 with the
agouti allele) were purchased from Knockout Mouse Project Repository (KOMP). The ES cells
were microinjected into albino B6 mice blastocysts using standard techniques.[27] The chime-
ric mice were generated and mated to obtain homozygous KO mice. These mice are now avail-
able from Jackson Laboratories (Stock No. 028838 C57BL/6N-Arhgef3<tm1(KOMP)Wtsi>/
DkrsJ). For all experiments, wild-type (WT) littermates served as controls. All mouse pro-
cedures were performed according to Yale University Animal Care and Use Committee-
approved protocols and complied with federal laws.
Quantitative RT-PCR
RNA from 5x104 cells was isolated using the RNAqueous-Micro Kit (Life Technology,
Carlsbad, CA), and treated with RNase-free DNase I. First-strand cDNA was produced with
iScript™ cDNA Synthesis Kit (Bio-Rad, Hercules, CA) with 20 ng RNA from each sample.
Gene expression levels were quantified on an iCycler iQ RT machine (Bio-Rad, Hercules, CA,
USA) with 2 ul of cDNA product from each sample using TaqMan probes (Applied Biosys-
tems, Carlsbad, CA) as follows: murine ARHGEF3: Mm00551104_m1 and Eukaryotic18S
rRNA: Hs99999901_s1. Relative gene levels were calculated from standard curves and normal-
ized to 18 s levels.
Beta-galactosidase staining on mouse fetal liver section
Day 13.5 mouse embryos from WT and Arhgef3 KO were harvested and whole embryo fixa-
tion and beta-galactosidase staining was carried out according to the manual protocol from
the Cellular Senescence Assay kit (Millipore, Billerica, MA, USA). After beta-galactosidase
staining, whole embryos were mounted in tissue TeK (Sakura Finetek, USA) and stored at
-80˚C. 7μm frozen sections including liver tissue, were mounted onto lysine coated slides
(Sigma, St. Louis, MO, USA) and allowed to air dry. Immunohistochemistry was carried out
using a primary rat-anti mouse CD41 (BD, USA) and a secondary biotinylated goat anti-rat
IgG antibody, and developed using the 3,3’diaminobenzidine (DAB) substrate kit for peroxi-
dase (Vector laboratories, Burlingame, CA, USA). Nuclei were counterstained with nuclear
fast red (Sigma, St. Louis, MO, USA) and Digital images captured using an Axiocam (Zeiss,
Thornwood, NY, USA) camera mounted onto an Axioskop fluorescent microscope (Zeiss).
Isolation and culture of murine bone marrow cells
Hips, femurs, and tibias of 4–6 week-old mice were dissected and isolated. Bone marrow was
obtained after crushing in ice-cold PBS containing 1% fetal bovine serum (FBS). Following cen-
trifugation, red blood cell lysis (BD Pharmlyse, San Jose, CA) was performed. Next, cells were
washed with PBS containing 2 mM EDTA and further cultured or stained for flow cytometry
analysis. For MK differentiation, bone marrow cells were grown at 5x106 cells/ml in StemSpan
(StemCell Technologies, Vancouver, Canada) supplemented with 30% BIT9500 (StemCell
Technologies) plus 20 ng/ml murine TPO for a total of 4 days before flow cytometry analysis.
Flow cytometric analysis of DNA content and surface markers
Fresh bone marrow cells or in vitro differentiated MK were stained with FITC-conjugated
anti-CD41 antibody, then fixed and permeabilized using 70% Ethanol at 4˚C overnight. After
ARHGEF3 in megakaryocytes and platelets
PLOS ONE | https://doi.org/10.1371/journal.pone.0178095 May 23, 2017 11 / 16
incubation with 4 ug/ml RNAase at 37˚C for 4 hr, nuclear DNA was stained with 1g/ml propi-
dium iodide (Company) and analyzed using a FACS Calibur cytometer (BD Biosciences, San
Jose, CA) and FlowJo software (TreeStar, Ashland, OR).
Determination of bleeding times
Using a sharp razor blade, 0.5 cm of the tail was removed and the tail held in warm PBS. Time
until cessation of tail bleeding was measured. Persistent bleeding was terminated after 5
minutes.
Murine platelet preparation and analysis
For platelet counts, peripheral blood was collected from the retro-orbital sinus using EDTA
coated tubes, and assessed using a Hemavet Analyzer (Drew Scientific, FL). For functional
platelet assays, blood was collected into heparinized tubes (BD Biosciences, San Jose, CA).
Platelet-rich plasma was prepared as previously described (REF). For flow cytometry, 50 uL of
whole blood was added to 200 uL Tris-buffered saline (20mM Tris-HCl, 137mM NaCl). After
further dilution with 1 mL of 2 mM CaCl2 in modified Tyrodes-HEPES buffer (5mM HEPES,
140mM NaCl, 2.7mM KCl, 5.5mM dextrose, 0.42mM Na2HPO4, 12mM NaHCO3), platelets
were stained with anti-GPIIb/IIIa (CD41/61) FITC together with anti-GPIIb/IIIa (CD41/61)
PE (JONA clone) or anti-P-selectin PE (Emfret, Wu¨rzburg, Germany). During staining, plate-
lets were also stimulated with 1mM adenosine 5-diphosphate (ADP; Sigma-Aldrich, St. Louis,
MO, USA), 0.1U or 0.01U Thrombin (Roche, Basel, Switzerland), or 3mM Thromboxane A2
analog U46619 (Cayman Chemical, Ann Arbor, MI, USA) at 37˚C for 20min. Reactions were
stopped by adding 300 ul 0.5% PFA (in PBS) to the samples and analyzed using a FACS Cali-
bur cytometer (BD Biosciences, San Jose, CA, USA) and FlowJo software (TreeStar, Ashland,
OR, USA).
Transient immunothrombocytopenia model
To induce transient thrombocytopenia, 4-week-old mice were intravenously injected with
2 μg/g body weight of anti-GPIb antibody (R300; Emfret, Wu¨rzburg, Germany). Platelet
counts were then assessed every other day for 10 days with the Hemavet Analyzer (Drew Sci-
entific, Texas, USA).
Human megakaryocyte differentiation
CD34+ progenitor cells were isolated and enriched from cord blood as reported previously.
(51) MK cultures of 105 cells/ml were supplemented with 100 ng/ml thrombopoietin (rhTPO
CellGenix, Freiburg, Germany) and 10 ng/ml IL1b (R&D, Minneapolis, MN, USA) in CellGro
media (CellGenix, Freiburg, Germany). Media and cytokines were rejuvenated at days 3 and 6.
At day 10, mature MKs were immunopurified using an anti-CD42b PE conjugated antibody
(Pab5, NHS Blood and Transplant, IBGRL, Bristol, England) and a PE positive selection kit
(STEMCELL Technologies, Vancouver, Canada). MK purity was verified by FACS and shown
to be>95% for CD41a (BD, San Jose, CA, USA) and CD42b (IBGRL, Bristol, England).
Human platelet function association study
Healthy individuals (366 females and 501 males, of predominantly Northern European origin)
were recruited in the two phases. First 500 in Platelet Function Cohort (PFC) 1 in 2007, and
the remaining ones in 2010–2011. Of the 500 PFC-1 samples, 480 were genotyped using the
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genomewide platform Illumina 610K.[28] The PFC-2 samples were genotyped using the
genome-wide platform, Illumina OmniExpress.
Functional response of platelets was measured for P-selectin expression and fibrinogen
binding on platelets in response to activation with a mid-range dose of ADP and the cross-
linked (XL) collagen mimetic collagen related peptide (CRP) using the protocol described by
Jones et al. [29] The 67 sentinel SNPs (excluding HLA-B and HLA-DOA to reduce any spuri-
ous associations) that were previously found to be associated to either platelet count or volume
[5] were tested for association with platelet function as described by Jones et al. [29] The asso-
ciation study was carried out using an additive model that corrected for batch effects of PFC1
and PFC2.
Expression quantitative trait locus (eQTL) analysis
Genotyping for rs1354034 was obtained from 154 healthy human subjects of the Platelet RNA
and eXpression study-1 (PRAX1) using the Illumina HumanOmni5 platform, as described
previously. [30] ARHGEF3 expression levels on the same 154 PRAX1 subjects were profiled
using the Affymetrix HuGeneST1.0 platform, as described previously. [11] Association
between allele dosage of rs1354034 and ARHGEF3 expression levels was tested using simple
and multiple linear regression models. In the simple model allele dosage and ARHGEF3
expression levels were used as the explanatory and dependent variables, respectively. In the
multiple linear regression model, allele dosage was used to explain ARHGEF3 expression levels
after accounting for the subjects’ age, gender and race.
Statistical analysis
Statistical significance was assessed set at P<0.05 and using Prism 6.0 software (GraphPad
Software) using the standard t-test statistical analysis.
Human subjects
All research involving human participants was approved by the authors’ Institutional Review
Boards, and all clinical investigation was conducted according to the principles expressed in
the Declaration of Helsinki. Written informed consent was obtained from the participants.
Subjects participating in the Cambridge Platelet Function cohort study (Cambridge, UK) pro-
vided written signed consent under Research Ethics Committee (REC) reference number
05/Q0104/27 approved by Huntingdon Research Ethics Committee and Cambridgeshire
Research Ethics Committee. The epigenome studies were executed as part of the BLUEPRINT
consortium studies and subjects participating in the BLUEPRINT study (Cambridge, UK) pro-
vided their written signed consent under the Research Ethics Committee approved study with
REC reference number 12/EE/0040 by the NRES Committee East of England, Hatfield. The
TEMPLE targeted sequencing of the extended ARHGEF3 locus was performed with DNA
samples from participants in the Lifelines Cohort Study in the Netherlands. These participants
provided written signed consent under the Ethics Committee approved study with CCMO ref-
erence number NL17981.042.07.
Supporting information
S1 Fig. rs1354034 has different allele frequencies in the African American and Caucasian
populations.
(TIF)
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S2 Fig. Arhgef3 KO mice have normal progenitor cell population in the bone marrow and
normal MK differentiation. (A) Progenitor cell population analysis by flow cytometry in
fresh isolated bone marrow cells from WT and Arhgef3 KO mice showed no difference in pro-
genitor population. (B) Megakaryocyte ploidy and maturation assessment from freshly isolated
(left) or 4 day in vitro differentiation (right) bone marrow cells shows no defects of MK matu-
ration in the Arhgef3 KO.
(TIF)
S1 Table. Raw data for data shown in S1 Fig.
(PDF)
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